Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Guggenheim to “Hold”

Guggenheim lowered shares of Vigil Neuroscience (NASDAQ:VIGL) from a strong-buy rating to a hold rating in a research report report published on Thursday morning,Zacks.com reports.

VIGL has been the subject of several other research reports. Citigroup cut Vigil Neuroscience to a “market perform” rating in a research note on Thursday. HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, March 14th. Citizens Jmp downgraded Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. William Blair downgraded Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. Finally, Jefferies Financial Group downgraded Vigil Neuroscience to a “hold” rating in a report on Thursday. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.00.

Vigil Neuroscience Price Performance

VIGL stock opened at $7.89 on Thursday. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $7.95. The business has a fifty day moving average price of $2.19 and a 200-day moving average price of $2.30. The stock has a market capitalization of $368.24 million, a P/E ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, analysts anticipate that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC grew its position in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares in the last quarter. Northern Trust Corp grew its position in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after purchasing an additional 14,572 shares in the last quarter. Barclays PLC grew its position in shares of Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after purchasing an additional 19,436 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock worth $233,000 after purchasing an additional 41,836 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Vigil Neuroscience during the fourth quarter worth about $83,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.